YEEHAW CANDIDATES Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Galirayo	6/9/2005 11:16:23 AM
	Read Replies (1) of 23958

[AMLN] I added it back in .. It's one of Peters [BioMaven]. stockcharts.com[w,a]dacayiay[dd][pb50!h.02,.20!f][vc60][iut!Ua12,26,9!Uv25]&pref=G Newly Approved First-in-Class Treatment for Type 2 Diabetes Is Now Available Thursday June 9, 8:00 am ET -- Amylin and Lilly Launch BYETTA(TM) (exenatide) injection for type 2 diabetes patients unable to control disease with common oral therapies -- SAN DIEGO, and INDIANAPOLIS, June 9 /PRNewswire-FirstCall/ -- BYETTA(TM) (exenatide) injection is now available for Americans struggling to control their type 2 diabetes. BYETTA can help diabetes patients manage blood sugar while potentially losing weight. Recently approved by the Food and Drug Administration (FDA), BYETTA is now available in pharmacies across the country. [snip] biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next